Cannabidiol for the Management of Endometriosis and Chronic Pelvic Pain

Mistry, Megha; Simpson, Paul; Morris, Edward; Fritz, Ann-Katrin; Karavadra, Babu; Lennox, Carole; Prosser-Snelling, Ed

doi:10.1016/j.jmig.2021.11.017

Cited by 10 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…adjunct to pain and 13% of these reported the use of cannabis to control symptoms. In addition, it is noteworthy that the use of medicinal cannabis can be administered orally 31 .…”

Section: Treatment Of Endometriosis With Cannabidiol and Its Adverse ...mentioning

confidence: 99%

“…In contrast to the adverse events associated with the use of cannabis reported, 10% had effects such as drowsiness, increased anxiety or tachycardia, these being the most common. However, it was concluded that the potential benefits of cannabis may outweigh the harms and that long-term data are lacking 31 .…”

Section: Treatment Of Endometriosis With Cannabidiol and Its Adverse ...mentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic use of cannabidiol in endometriosis: literature review

Leão,

Strobel,

Fiorentino

et al. 2023

JHS

View full text Add to dashboard Cite

Objective: Expose existing therapies for the treatment and monitoring of endometriosis, delving into the use of cannabidiol as a new therapeutic form. Methods: A narrative review of the literature was carried out based on 37 articles that ranged between 2004 and 2022 between March and May 2023. The bibliography included the Portuguese and English languages, preferably from the last 5 years, and were taken from the SciElo databases, PubMed, Web of Science and Scopus. Results: The clinical picture of endometriosis is variable. Symptoms are associated with dysmenorrhea, dyspareunia, infertility, chronic pelvic pain, chronic fatigue, ovulatory pain, urinary or intestinal complaints. In patients in whom the clinical condition of endometriosis is minimal, initial treatment can be with progestogens or combined oral contraceptives (OC). There is evidence that cannabis acts to improve pain, quality of life and decrease complications. The vast majority report improvement in sleep quality, decrease in symptoms of nausea and vomiting. Added to this, they were able to completely discontinue medication use, with opioids being the most common class of discontinued analgesics. Current treatment options for endometriosis often affect fertility and can cause undesirable side effects that preclude long-term management of this condition. Conclusion: The main treatments are based on NSAIDs and opioids and, if used chronically, they can cause harm. Therefore, cannabis-based drugs are alternatives to conventional therapies, as they improve pain symptoms, enabling quality of life and reducing complications.

show abstract

“…adjunct to pain and 13% of these reported the use of cannabis to control symptoms. In addition, it is noteworthy that the use of medicinal cannabis can be administered orally 31 .…”

Section: Treatment Of Endometriosis With Cannabidiol and Its Adverse ...mentioning

confidence: 99%

Section: Treatment Of Endometriosis With Cannabidiol and Its Adverse ...mentioning

confidence: 99%

Therapeutic use of cannabidiol in endometriosis: literature review

Leão,

Strobel,

Fiorentino

et al. 2023

JHS

View full text Add to dashboard Cite

show abstract

“…Likewise, its participation in neurotransmission systems such as serotonergic, GABAergic and glutamatergic has the power to mitigate anxiety and decrease nausea [ 311 ]. Despite the facts, the lack of clinical evidence in patients with MDD or patients who have other particularities that could increase the risk of developing MDD in women (endometriosis or loss of quality of life in pregnancy) means that its use cannot be recommended [ 313 , 314 , 315 ]. It can be concluded that future research is necessary to discover the advantages that this nutraceutical provides in the particularities of the MDD pathology.…”

Section: Nutritional Intervention In Women With Mddmentioning

confidence: 99%

The Problem of Malnutrition Associated with Major Depressive Disorder from a Sex-Gender Perspective

et al. 2022

View full text Add to dashboard Cite

Major depressive disorder (MDD) is an incapacitating condition characterized by loss of interest, anhedonia and low mood, which affects almost 4% of people worldwide. With rising prevalence, it is considered a public health issue that affects economic productivity and heavily increases health costs alone or as a comorbidity for other pandemic non-communicable diseases (such as obesity, cardiovascular disease, diabetes, inflammatory bowel diseases, etc.). What is even more noteworthy is the double number of women suffering from MDD compared to men. In fact, this sex-related ratio has been contemplated since men and women have different sexual hormone oscillations, where women meet significant changes depending on the age range and moment of life (menstruation, premenstruation, pregnancy, postpartum, menopause…), which seem to be associated with susceptibility to depressive symptoms. For instance, a decreased estrogen level promotes decreased activation of serotonin transporters. Nevertheless, sexual hormones are not the only triggers that alter neurotransmission of monoamines and other neuropeptides. Actually, different dietary habits and/or nutritional requirements for specific moments of life severely affect MDD pathophysiology in women. In this context, the present review aims to descriptively collect information regarding the role of malnutrition in MDD onset and course, focusing on female patient and especially macro- and micronutrient deficiencies (amino acids, ω3 polyunsaturated fatty acids (ω3 PUFAs), folate, vitamin B12, vitamin D, minerals…), besides providing evidence for future nutritional intervention programs with a sex-gender perspective that hopefully improves mental health and quality of life in women.

show abstract

“…The expanding legalization of recreational cannabinoids has led to a recent surge in the use of cannabinoids as a form of self-management therapy for many diseases, including EMS (Carrubba et al 2021;Sinclair et al 2019). Several articles in the past have thoroughly discussed the use and effectiveness of cannabinoids for pain management in EMS patients and the broad role of ECS in reproductive disorders (Mistry et al 2022;Bouaziz et al 2017;Maia et al 2020). One of the recent meta-analyses conducted by Mistry et al reviewed the effects of cannabis-based products on female reproductive health in the context of EMS and chronic pelvic pain and suggested that fertility complications and long-term cognitive functions might be affected.…”

Section: Introductionmentioning

confidence: 99%

“…One of the recent meta-analyses conducted by Mistry et al reviewed the effects of cannabis-based products on female reproductive health in the context of EMS and chronic pelvic pain and suggested that fertility complications and long-term cognitive functions might be affected. Additionally, the authors also acknowledge the lack of thorough and reliable evidence to support or dismiss the use of cannabinoids to treat EMS symptoms (Mistry et al 2022). Similarly, a study conducted by Bouaziz et al in 2017 summarized the role of ECS in EMS-associated pain symptoms and the potential use of cannabinoids as therapeutic agents, where they concluded that pain mechanisms are heterogenous in EMS patients and the use of cannabinoids for the treatment of EMS needs to be evaluated carefully (Bouaziz et al 2017).…”

Section: Introductionmentioning

confidence: 99%

Role of the endocannabinoid system in the pathophysiology of endometriosis and therapeutic implications

et al. 2022

View full text Add to dashboard Cite

Endometriosis patients experience debilitating chronic pain, and the first-line treatment is ineffective at managing symptoms. Although surgical removal of the lesions provides temporary relief, more than 50% of the patients experience disease recurrence. Despite being a leading cause of hysterectomy, endometriosis lacks satisfactory treatments and a cure. Another challenge is the poor understanding of disease pathophysiology which adds to the delays in diagnosis and overall compromised quality of life. Endometriosis patients are in dire need of an effective therapeutic strategy that is both economical and effective in managing symptoms, while fertility is unaffected. Endocannabinoids and phytocannabinoids possess anti-inflammatory, anti-nociceptive, and anti-proliferative properties that may prove beneficial for endometriosis management, given that inflammation, vascularization, and pain are hallmark features of endometriosis. Endocannabinoids are a complex network of molecules that play a central role in physiological processes including homeostasis and tissue repair, but endocannabinoids have also been associated in the pathophysiology of several chronic inflammatory diseases including endometriosis and cancers. The lack of satisfactory treatment options combined with the recent legalization of recreational cannabinoids in some parts of the world has led to a rise in self-management strategies including the use of cannabinoids for endometriosis-related pain and other symptoms. In this review, we provide a comprehensive overview of endocannabinoids with a focus on their potential roles in the pathophysiology of endometriosis. We further provide evidence-driven perspectives on the current state of knowledge on endometriosis-associated pain, inflammation, and therapeutic avenues exploiting the endocannabinoid system for its management.

show abstract

Cannabidiol for the Management of Endometriosis and Chronic Pelvic Pain

Cited by 10 publications

References 47 publications

Therapeutic use of cannabidiol in endometriosis: literature review

Therapeutic use of cannabidiol in endometriosis: literature review

The Problem of Malnutrition Associated with Major Depressive Disorder from a Sex-Gender Perspective

Role of the endocannabinoid system in the pathophysiology of endometriosis and therapeutic implications

Contact Info

Product

Resources

About